Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

Merck IO Drug Extends Lead As Obesity Drugs Climb Table

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Close,Up,Of,Syringe,With,Money,Injection,On,Dollar,Banknotes
Best-selling drugs generate billions of dollars (Shutterstock)

Strong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ahead of its closest rival for the position of best-selling drug globally.

The GLP-1 inhibitors continued to exert their force over the global medicines market. Novo Nordisk’s Ozempic (semaglutide) for type 2...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Earnings